Möchten Sie immer auf dem neuesten Stand bleiben?

Fremont, CA, July 28, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to advancing the early detection of disease, today announced the...

WATERTOWN, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...

Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera’s industry-leading oral immunology portfolio Jared Gollob, MD, will retire from...

Oncolytics announced the FDA has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for squamous cell anal cancer.

Trethera and UCLA publish peer-reviewed manuscript highlighting dCK as a novel cancer target and TRE-515 as the first clinically tested dCK inhibitor

Examines the evolving competitive landscape, regulatory developments & investment trends shaping the future of chronic kidney disease management worldwide.

Teva-discovered TEV-’408 targets IL-15, a key driver of vitiligo biology TEV-’408 showed improvement in skin pigmentation and was well-tolerated with no safety signals observed to dateNearly 75% of...

Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end...

Dublin, July 06, 2026 (GLOBE NEWSWIRE) -- The "Fair-Market Value Compensation Rates for Rheumatology KOLs - United States" has been added to ResearchAndMarkets.com's offering. The Thought...

VERAXA Biotech announces further progress with lead BiTAC® T-cell engager (BiTAC-TCE) program, initiates cell line development with ATUM.